A Phase II Study of Peripheral Blood Stem Cell Transplantation (PBSCT)From Haploidentical Related Donors for Treatment of Hematologic Malignancies and Hematopoietic Failure States.

Trial Profile

A Phase II Study of Peripheral Blood Stem Cell Transplantation (PBSCT)From Haploidentical Related Donors for Treatment of Hematologic Malignancies and Hematopoietic Failure States.

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Aug 2016

At a glance

  • Drugs Alemtuzumab (Primary) ; Busulfan (Primary) ; Melphalan (Primary)
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Aplastic anaemia; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Hodgkin's disease; Multiple myeloma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Paroxysmal nocturnal haemoglobinuria
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Mar 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 02 Mar 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 01 Feb 2013 Planned End Date changed from 1 Feb 2012 to 1 Feb 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top